Exiting Danaher Position with 7% Loss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 26 2026
0mins
Should l Buy DHR?
Source: CNBC
- Position Reduction: We sold 200 shares of Danaher at approximately $208 each on Thursday, resulting in a disappointing 7% loss on shares purchased between 2023 and 2025, reflecting our disillusionment with the company's future performance.
- Weak Growth: Despite our hopes for Danaher's bioprocessing business to recover post-COVID, its revenue growth has failed to achieve consistent high single-digit percentages, prompting us to clean up our portfolio to free up space for new opportunities.
- Lack of Confidence in Acquisitions: Our confidence in Danaher's recent acquisition strategy has waned, particularly as the acquisitions of Abcam and Aldevron did not drive performance as expected, deepening our pessimism regarding their acquisition of Masimo.
- Legal Risk Consideration: Given the longstanding legal battle between Apple and Masimo, which could pose additional risks for Danaher in the future, we are more inclined to seek alternative investment opportunities.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DHR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DHR
Wall Street analysts forecast DHR stock price to rise
18 Analyst Rating
17 Buy
1 Hold
0 Sell
Strong Buy
Current: 193.780
Low
240.00
Averages
266.18
High
310.00
Current: 193.780
Low
240.00
Averages
266.18
High
310.00
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a broad range of instruments, consumables, services and software that are primarily used by customers to study the basic building blocks of life, including deoxyribonucleic acid (DNA) and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Wall Street Earnings Season Faces Major Test
- Earnings Season Significance: Wall Street is set for a packed earnings season featuring key companies like Capital One and Boeing, with investors eager to glean insights into the economic impact of the Iran war from these reports.
- Capital One Performance Focus: Capital One is scheduled to report earnings on Tuesday, with market attention on its consumer health metrics and the progress of its acquisitions of Discover and Brex, particularly amid rising economic uncertainties.
- Boeing Earnings Outlook: Boeing is expected to release its earnings report on Wednesday, with market focus on order volumes in both its commercial and defense sectors, as well as free cash flow performance, especially after previous unexpected losses.
- GE Vernova Order Growth: GE Vernova will report alongside Boeing, with first-quarter new orders anticipated to reach $14.4 billion, reflecting a 65% year-over-year increase, indicating strong market performance amid rising electricity demand.
See More
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Wall Street Optimism Rises Amid Ceasefire Hopes
- Market Rebound: The S&P 500 and Nasdaq Composite reached all-time highs this week, with the S&P 500 surpassing 7,100 for the first time, reflecting strong investor confidence in economic recovery and suggesting further upward momentum for equities.
- Earnings Expectations: According to FactSet, the S&P 500 is projected to have a blended growth rate of 12.5% in Q1, with 78% of reporting companies exceeding expectations, providing a positive backdrop for the upcoming earnings season that could further bolster market confidence.
- Oil Price Volatility: While oil prices have fallen to around $80 per barrel, significantly below the $110 peak during the conflict, the market must remain vigilant regarding the potential impacts of U.S.-Iran tensions on global supply chains, particularly concerning the safety of transit through the Strait of Hormuz.
- Technical Fragility: Despite the market's strong short-term performance, analyst Craig Johnson warns that the rapid transition from oversold to overbought conditions masks underlying macroeconomic risks, urging investors to remain cautious and focus on high-quality investment opportunities.
See More
Market Preview: Oil Prices Drop, iPhone Shipments Surge
- Oil Price Decline: Oil prices fell approximately 10% after Iran declared the Strait of Hormuz open for commercial traffic during a 10-day ceasefire between Israel and Lebanon, which could negatively impact the earnings of related energy companies.
- Surge in iPhone Shipments: According to CounterPoint Research, iPhone shipments in China increased by 20% in Q1, despite an overall decline in the smartphone market due to soaring memory costs, providing a positive outlook for Apple's primary revenue source.
- Netflix Price Target Cuts: Barclays lowered Netflix's price target from $115 to $110, with Wolfe Research and Rosenblatt also cutting theirs to $107 and $95 respectively, leading to a more than 9% drop in shares, reflecting market concerns about its future performance.
- Target Price Adjustments: Several companies, including Danaher and Abbott Laboratories, saw their price targets cut, with Danaher's target reduced from $220 to $205 due to concerns over its legacy business, while Abbott's target was lowered to $120 by multiple firms, although all maintained a buy rating.
See More
New Assay Could Save €80M for European Health Systems
- Cost Savings Potential: The introduction of the Access MeMed BV assay could help European healthcare systems avoid up to €80 million annually by reducing unnecessary admissions and testing, thereby optimizing resource allocation and lowering healthcare expenditures.
- Rapid Diagnostic Capability: This assay differentiates between bacterial and viral infections in approximately 20 minutes, leveraging existing DxI 9000 and Access 2 immunoassay analyzers, significantly enhancing clinical decision-making efficiency and enabling timely treatment choices for clinicians.
- Clinical Decision Support: In real-world studies involving nearly 6,000 patients, 82-87% of physicians reported that MeMed BV results supported or changed their clinical decisions, effectively reducing unnecessary antibiotic use and advancing antimicrobial stewardship initiatives.
- Economic Benefit Validation: Independent health-economic modeling indicates that incorporating MeMed BV into routine care could generate substantial savings, with £134,018 saved for adults and £105,750 for pediatric patients per 1,000 evaluated for suspected community-acquired pneumonia, highlighting its significant value in reducing hospitalizations and diagnostic procedures.
See More
New Assay Could Save €80M for European Health Systems
- Cost Savings Potential: The Access MeMed BV assay from Beckman Coulter Diagnostics could help European healthcare systems save up to €80 million annually by reducing unnecessary admissions and testing, significantly lowering healthcare expenditures and optimizing resource allocation.
- Rapid Testing Advantage: This assay provides rapid differentiation between bacterial and viral infections in approximately 20 minutes, leveraging existing DxI 9000 and Access 2 immunoassay analyzers, enhancing clinical decision-making efficiency and enabling more informed antibiotic use by physicians.
- Clinical Decision Support: In real-world studies involving nearly 6,000 patients, 82-87% of physicians reported that MeMed BV results supported or changed their clinical decisions, effectively reducing unnecessary antibiotic use and advancing antimicrobial stewardship initiatives.
- Economic Benefit Validation: Economic modeling indicates that for every 1,000 patients evaluated for suspected community-acquired pneumonia, incorporating MeMed BV can generate £134,018 in cost savings for adults and £105,750 for pediatric care, demonstrating the assay's significant value in improving healthcare efficiency.
See More
Wall Street Earnings Season Faces Major Test
- Earnings Season Significance: Wall Street is set for a packed earnings season featuring key companies like Capital One and Boeing, with investors eager to glean insights into the economic impact of the Iran war from these reports.
- Capital One Performance Focus: Capital One is scheduled to report earnings on Tuesday, with market attention on its consumer health metrics and the progress of its acquisitions of Discover and Brex, particularly amid rising economic uncertainties.
- Boeing Earnings Outlook: Boeing is expected to release its earnings report on Wednesday, with market focus on order volumes in both its commercial and defense sectors, as well as free cash flow performance, especially after previous unexpected losses.
- GE Vernova Order Growth: GE Vernova will report alongside Boeing, with first-quarter new orders anticipated to reach $14.4 billion, reflecting a 65% year-over-year increase, indicating strong market performance amid rising electricity demand.
See More
Apple Wins Patent Dispute Against Masimo
- Patent Dispute Outcome: The U.S. International Trade Commission ruled in favor of Apple (AAPL) in its patent dispute with medical device maker Masimo (MASI), rejecting Masimo's request for an import ban on certain Apple Watch models, demonstrating Apple's legal strength in technology competition.
- Legal Battle History: Since 2021, Masimo has accused Apple of poaching key engineers and stealing its developed pulse oximetry technology, and despite launching multiple lawsuits over six years, nearly all claims have been dismissed, reflecting Apple's robust legal defense capabilities.
- Market Reaction: At the time of this announcement, retail sentiment around MASI and AAPL stocks remained in the 'bullish' territory, with MASI stock gaining 17% over the past 12 months and AAPL stock rising 37%, indicating strong market confidence in Apple.
- Future Outlook: Although Masimo can appeal the decision to the U.S. Court of Appeals for the Federal Circuit, Apple's victory may further solidify its leadership in the smartwatch market and reduce future legal risks.
See More
Wall Street Optimism Rises Amid Ceasefire Hopes
- Market Rebound: The S&P 500 and Nasdaq Composite reached all-time highs this week, with the S&P 500 surpassing 7,100 for the first time, reflecting strong investor confidence in economic recovery and suggesting further upward momentum for equities.
- Earnings Expectations: According to FactSet, the S&P 500 is projected to have a blended growth rate of 12.5% in Q1, with 78% of reporting companies exceeding expectations, providing a positive backdrop for the upcoming earnings season that could further bolster market confidence.
- Oil Price Volatility: While oil prices have fallen to around $80 per barrel, significantly below the $110 peak during the conflict, the market must remain vigilant regarding the potential impacts of U.S.-Iran tensions on global supply chains, particularly concerning the safety of transit through the Strait of Hormuz.
- Technical Fragility: Despite the market's strong short-term performance, analyst Craig Johnson warns that the rapid transition from oversold to overbought conditions masks underlying macroeconomic risks, urging investors to remain cautious and focus on high-quality investment opportunities.
See More
Market Preview: Oil Prices Drop, iPhone Shipments Surge
- Oil Price Decline: Oil prices fell approximately 10% after Iran declared the Strait of Hormuz open for commercial traffic during a 10-day ceasefire between Israel and Lebanon, which could negatively impact the earnings of related energy companies.
- Surge in iPhone Shipments: According to CounterPoint Research, iPhone shipments in China increased by 20% in Q1, despite an overall decline in the smartphone market due to soaring memory costs, providing a positive outlook for Apple's primary revenue source.
- Netflix Price Target Cuts: Barclays lowered Netflix's price target from $115 to $110, with Wolfe Research and Rosenblatt also cutting theirs to $107 and $95 respectively, leading to a more than 9% drop in shares, reflecting market concerns about its future performance.
- Target Price Adjustments: Several companies, including Danaher and Abbott Laboratories, saw their price targets cut, with Danaher's target reduced from $220 to $205 due to concerns over its legacy business, while Abbott's target was lowered to $120 by multiple firms, although all maintained a buy rating.
See More
New Assay Could Save €80M for European Health Systems
- Cost Savings Potential: The introduction of the Access MeMed BV assay could help European healthcare systems avoid up to €80 million annually by reducing unnecessary admissions and testing, thereby optimizing resource allocation and lowering healthcare expenditures.
- Rapid Diagnostic Capability: This assay differentiates between bacterial and viral infections in approximately 20 minutes, leveraging existing DxI 9000 and Access 2 immunoassay analyzers, significantly enhancing clinical decision-making efficiency and enabling timely treatment choices for clinicians.
- Clinical Decision Support: In real-world studies involving nearly 6,000 patients, 82-87% of physicians reported that MeMed BV results supported or changed their clinical decisions, effectively reducing unnecessary antibiotic use and advancing antimicrobial stewardship initiatives.
- Economic Benefit Validation: Independent health-economic modeling indicates that incorporating MeMed BV into routine care could generate substantial savings, with £134,018 saved for adults and £105,750 for pediatric patients per 1,000 evaluated for suspected community-acquired pneumonia, highlighting its significant value in reducing hospitalizations and diagnostic procedures.
See More
New Assay Could Save €80M for European Health Systems
- Cost Savings Potential: The Access MeMed BV assay from Beckman Coulter Diagnostics could help European healthcare systems save up to €80 million annually by reducing unnecessary admissions and testing, significantly lowering healthcare expenditures and optimizing resource allocation.
- Rapid Testing Advantage: This assay provides rapid differentiation between bacterial and viral infections in approximately 20 minutes, leveraging existing DxI 9000 and Access 2 immunoassay analyzers, enhancing clinical decision-making efficiency and enabling more informed antibiotic use by physicians.
- Clinical Decision Support: In real-world studies involving nearly 6,000 patients, 82-87% of physicians reported that MeMed BV results supported or changed their clinical decisions, effectively reducing unnecessary antibiotic use and advancing antimicrobial stewardship initiatives.
- Economic Benefit Validation: Economic modeling indicates that for every 1,000 patients evaluated for suspected community-acquired pneumonia, incorporating MeMed BV can generate £134,018 in cost savings for adults and £105,750 for pediatric care, demonstrating the assay's significant value in improving healthcare efficiency.
See More
